Chapter title |
Engineering therapeutic cancer vaccines that activate antitumor immunity.
|
---|---|
Chapter number | 15 |
Book title |
RNA Interference
|
Published in |
Methods in molecular biology, September 2014
|
DOI | 10.1007/978-1-4939-1538-5_15 |
Pubmed ID | |
Book ISBNs |
978-1-4939-1537-8, 978-1-4939-1538-5
|
Authors |
Per Ole Iversen, Mouldy Sioud, Iversen, Per Ole, Sioud, Mouldy |
Abstract |
Vaccination represents one the most effective methods of preventing disease. Because dendritic cells (DCs) are the most efficient antigen presenting cells, exploiting their plasticity is likely to yield improved therapeutic vaccines. Herein, we applied a novel DC-based vaccine (i.e., DC loaded with leukemia antigens that have been transfected with an IL-10 siRNA capable of coordinately activating DCs via TLR7/8) in a rat model of acute myeloid leukemia. Leukemic rats treated with this new vaccine had less leukemic cell mass in their bone marrows and less extramedullar dissemination of the leukemic disease examined postmortem compared with rats given the control vaccine. Collectively, the new strategy demonstrates the possible usefulness of dual siRNAs as an immunomodulatory drug with antileukemic properties. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 11 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 3 | 27% |
Researcher | 2 | 18% |
Student > Ph. D. Student | 1 | 9% |
Other | 1 | 9% |
Student > Master | 1 | 9% |
Other | 1 | 9% |
Unknown | 2 | 18% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 4 | 36% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 9% |
Immunology and Microbiology | 1 | 9% |
Medicine and Dentistry | 1 | 9% |
Engineering | 1 | 9% |
Other | 0 | 0% |
Unknown | 3 | 27% |